Abstract
RET (Rearranged during Transfection) is a transmembrane tyrosine kinase expressed in central and peripheral nervous system and neural crest-derived cells and acts as a co-receptor of GDNF family neurotrophic factor in complex with GRFα family proteins. RET protein comprises an extracellular portion with four cadherine-like domains and a cysteine- rich region important for intermolecular interactions; a hydrophobic transmembrane domain; an intracellular part comprising the juxtamembrane domain with regulatory function and the catalytic domain that phosphorylates the tyrosine residues of substrates. RET is involved in the development of enteric nervous system and renal organogenesis during embryonic life. Mutations of RET are associated to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer. Activating point mutations in the cystein-rich or the kinase domain of RET cause multiple endocrine neoplasia type 2 (MEN2), a group of familial cancer syndromes characterized by medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia and ganglioneuromatosis of the gastroenteric mucosa. Rearranged forms of RET (termed RET/PTC) are detected in the majority of papillary thyroid carcinomas (PTC). At present, the therapeutic treatment available for these pathologies is the total or partial surgical removal of thyroid, associated with radio-iodine therapy or chemotherapy: despite widespread use of multimodality treatment, survival rates have not improved much in the past few decades, which suggests that new treatment options should be explored. Several small-molecule inhibitors of RET kinase activity have been described in the last decade, some of which are currently undergoing clinical evaluation. Here, I review the large preclinical effort to the development of specific RET inhibitors, including medicinal chemistry analyses that may help refine potency and selectivity of future RET-targeted inhibitors.
Keywords: RET, tyrosine kinase, small-molecule inhibitor, thyroid cancer, PTC, target therapy, Rearranged during Transfection, renal organogenesis, colorectal cancer, medullary thyroid carcinoma, pheochromocy-toma, parathyroid hyperplasia, ganglioneuromatosis, gastroenteric mucosa, papillary thyroid carcinomas, cytotoxic agents, homeostasis, oncogenic factors, oncogene addiction, chronic myeloid leukemia, glial-derived neurotrophic factor, tyrosine residues (Tyr), spermatogonia, Hirsch-prung's disease, C-heli, multiple endocrine neoplasia (MEN), somatic mutations, lung carcinoma, heat shock protein 90 (Hsp90), herbimycin A, geldanamycin, genistein, imatinib, Staurosporine, pyrazolo-pyrimidine, valine, proteasome, quinazoline, autophosphorylation, bromofluorophenyl, methionine, methylpiperidin-methoxy, oxindole, quantitative analysis, Sorafenib, xenografts growth, Motesanib, Fostamatinib, spleen tyrosine kinase
Current Medicinal Chemistry
Title: Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Volume: 18 Issue: 2
Author(s): L. Mologni
Affiliation:
Keywords: RET, tyrosine kinase, small-molecule inhibitor, thyroid cancer, PTC, target therapy, Rearranged during Transfection, renal organogenesis, colorectal cancer, medullary thyroid carcinoma, pheochromocy-toma, parathyroid hyperplasia, ganglioneuromatosis, gastroenteric mucosa, papillary thyroid carcinomas, cytotoxic agents, homeostasis, oncogenic factors, oncogene addiction, chronic myeloid leukemia, glial-derived neurotrophic factor, tyrosine residues (Tyr), spermatogonia, Hirsch-prung's disease, C-heli, multiple endocrine neoplasia (MEN), somatic mutations, lung carcinoma, heat shock protein 90 (Hsp90), herbimycin A, geldanamycin, genistein, imatinib, Staurosporine, pyrazolo-pyrimidine, valine, proteasome, quinazoline, autophosphorylation, bromofluorophenyl, methionine, methylpiperidin-methoxy, oxindole, quantitative analysis, Sorafenib, xenografts growth, Motesanib, Fostamatinib, spleen tyrosine kinase
Abstract: RET (Rearranged during Transfection) is a transmembrane tyrosine kinase expressed in central and peripheral nervous system and neural crest-derived cells and acts as a co-receptor of GDNF family neurotrophic factor in complex with GRFα family proteins. RET protein comprises an extracellular portion with four cadherine-like domains and a cysteine- rich region important for intermolecular interactions; a hydrophobic transmembrane domain; an intracellular part comprising the juxtamembrane domain with regulatory function and the catalytic domain that phosphorylates the tyrosine residues of substrates. RET is involved in the development of enteric nervous system and renal organogenesis during embryonic life. Mutations of RET are associated to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer. Activating point mutations in the cystein-rich or the kinase domain of RET cause multiple endocrine neoplasia type 2 (MEN2), a group of familial cancer syndromes characterized by medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia and ganglioneuromatosis of the gastroenteric mucosa. Rearranged forms of RET (termed RET/PTC) are detected in the majority of papillary thyroid carcinomas (PTC). At present, the therapeutic treatment available for these pathologies is the total or partial surgical removal of thyroid, associated with radio-iodine therapy or chemotherapy: despite widespread use of multimodality treatment, survival rates have not improved much in the past few decades, which suggests that new treatment options should be explored. Several small-molecule inhibitors of RET kinase activity have been described in the last decade, some of which are currently undergoing clinical evaluation. Here, I review the large preclinical effort to the development of specific RET inhibitors, including medicinal chemistry analyses that may help refine potency and selectivity of future RET-targeted inhibitors.
Export Options
About this article
Cite this article as:
Mologni L., Development of RET Kinase Inhibitors for Targeted Cancer Therapy, Current Medicinal Chemistry 2011; 18 (2) . https://dx.doi.org/10.2174/092986711794088308
DOI https://dx.doi.org/10.2174/092986711794088308 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals Current Concepts and Future Directions in Radioimmunotherapy
Current Drug Discovery Technologies Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer
Current Genomics Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents